Table 3:

Investigator-assessed responses in black patients compared to non-black patients

	Mogamulizumab	Vorinostat
Confirmed overall response, n (%)
Black patients	7 (29.2)	1 (7.7)
Non-black patients	45 (27.8)	8 (4.6)
Response by compartment, n (%)
Skin compartment
Black patients	10 (41.7)	1 (7.7)
Non-black patients	68 (42.0)	28 (16.2)
Blood compartment
Black patients	13 (72.2)	1 (11.1)
Non-black patients	70 (66.0)	22 (19.0)
Nodal compartment
Black patients	2 (9.1)	1 (10.0)
Non-black patients	19 (16.7)	4 (3.3)
Visceral compartment
Black patients	0 (0.0)	N/A
Non-black patients	0 (0.0)	0 (0.0)
Best overall response by disease, n (%)
Black patients
Mycosis fungoides	7 (38.9)	1 (11.1)
Sézary syndrome	1 (16.7)	0 (0.0)
Non-black patients
Mycosis fungoides	18 (20.7)	8 (8.9)
Sézary syndrome	39 (52)	3 (3.6)